(Total Views: 456)
Posted On: 08/18/2021 8:15:15 AM
Post# of 72445
At the end of the GMU MANUSCRIPT comes this interesting line.
Insert-tag-hereThe results of the planned Phase 2 clinical trial, with intravenous treatment of COVID-19 in addition to standard of care, are highly anticipated.
In this manuscript, we demonstrated
1. brilacidin exhibits robust inhibition of SARS-CoV-2 in Vero cells and Calu-3 cells, and in two strains of the virus. Likely to function as a viral entry inhibitor. the proposed mechanism of action for brilacidin includes affecting the integrity of the viral membrane and interfering with viral entry.
2. Brilacidin also exhibited an excellent synergistic inhibitory profile against SARS-CoV-2 in combination with remdesivir. Destabilizing viral integrity is a desirable antiviral property, especially in relation to pan-coronavirus agents, as the viral membrane is highly conserved and similar in construct across different coronavirus strains.
Further research will be conducted in the context of other lethal coronaviruses (MERS-CoV, SARS-CoV) toward assessing the potential of brilacidin as a broad-spectrum inhibitor of coronaviruses.
Insert-tag-hereThe results of the planned Phase 2 clinical trial, with intravenous treatment of COVID-19 in addition to standard of care, are highly anticipated.
In this manuscript, we demonstrated
1. brilacidin exhibits robust inhibition of SARS-CoV-2 in Vero cells and Calu-3 cells, and in two strains of the virus. Likely to function as a viral entry inhibitor. the proposed mechanism of action for brilacidin includes affecting the integrity of the viral membrane and interfering with viral entry.
2. Brilacidin also exhibited an excellent synergistic inhibitory profile against SARS-CoV-2 in combination with remdesivir. Destabilizing viral integrity is a desirable antiviral property, especially in relation to pan-coronavirus agents, as the viral membrane is highly conserved and similar in construct across different coronavirus strains.
Further research will be conducted in the context of other lethal coronaviruses (MERS-CoV, SARS-CoV) toward assessing the potential of brilacidin as a broad-spectrum inhibitor of coronaviruses.
(0)
(0)
Ronald A Phillips
